Comparison of the Role of Losartan Alone vs Hydrochlorothiazide Plus Losartan
Status:
NOT_YET_RECRUITING
Trial end date:
2025-07-31
Target enrollment:
Participant gender:
Summary
Losartan, an angiotensin II receptor blocker, has already been established as a treatment for diabetic nephropathy due to its ability to reduce blood pressure and mitigate the progression of kidney damage. However, the addition of a diuretic like hydrochlorothiazide may offer synergistic benefits in reducing proteinuria by addressing both the underlying renal pathology and potential volume overload in these patients. The current study aims at determining and comparing the role of losartan alone vs hydrochlorothiazide plus losartan in reducing proteinuria in diabetic nephropathy patients.
Phase:
NA
Details
Lead Sponsor:
RESnTEC, Institute of Research
Treatments:
hydrochlorothiazide, losartan drug combination Losartan